N. Hynes and H. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors, Nature Reviews Cancer, vol.7, issue.5, pp.341-54, 2005.
DOI : 10.1021/jm00130a020

Z. Wang, L. Zhang, T. Yeung, and X. Chen, Endocytosis Deficiency of Epidermal Growth Factor (EGF) Receptor-ErbB2 Heterodimers in Response to EGF Stimulation, Molecular Biology of the Cell, vol.10, issue.5, pp.1621-1657, 1999.
DOI : 10.1091/mbc.10.5.1621

J. Baulida, M. Kraus, M. Alimandi, D. Fiore, P. Carpenter et al., All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired, J Biol Chem, vol.271, pp.5251-57, 1996.

A. Citri and Y. Yarden, EGF???ERBB signalling: towards the systems level, Nature Reviews Molecular Cell Biology, vol.96, issue.7, pp.505-521, 2006.
DOI : 10.1038/nrm1962

O. Reilly, E. Abou-alfa, and G. , Cytotoxic therapy for advanced pancreatic adenocarcinoma, Semin Oncol, vol.34, pp.347-53, 2007.

U. Graeven, B. Kremer, T. Sudhoff, B. Killing, F. Rojo et al., Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer, British Journal of Cancer, vol.29, issue.9, pp.1293-99, 2006.
DOI : 10.1200/JCO.2004.12.040

C. Larbouret, B. Robert, I. Navarro-teulon, S. Thezenas, M. Ladjemi et al., In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas, Clinical Cancer Research, vol.13, issue.11, pp.3356-62, 2007.
DOI : 10.1158/1078-0432.CCR-06-2302
URL : https://hal.archives-ouvertes.fr/inserm-00153693